Pretreatment of therapeutic cells with poly(ADP-ribose) polymerase inhibitor enhances their efficacy in an in vitro model of cell-based therapy in myocardial infarct

International Journal of Molecular Medicine

Volumn 31, Issue 1, 2013, Pages 26-32

  Szepes, Mónika ^a   Janicsek, Zsófia ^a   Benko, Zsolt ^a   Cselenyák, Attila ^a   Kiss, Levente ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cell based therapy; Ischemia reperfusion; Poly(ADP ribose) polymerase; Pretreatment

Indexed keywords

CALCEIN; FLUORESCENT DYE; HOMODIMER; LACTATE DEHYDROGENASE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; RESAZURIN;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL SURVIVAL; CELL THERAPY; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; IN VITRO STUDY; MYOBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION; REPERFUSION INJURY;

ANIMALS; CELL LINE; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FLOW CYTOMETRY; HYDRO-LYASES; MALONDIALDEHYDE; MYOCARDIAL INFARCTION; POLY(ADP-RIBOSE) POLYMERASES; RATS; REPERFUSION INJURY;

EID: 84873144517     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1186     Document Type: Article

References (41)

1. Dill T, Schachinger V, Rolf A, et al: Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am Heart J 157: 541-547, 2009.
2. Medicetty S, Wiktor D, Lehman N, et al: Percutaneous adventitial delivery of allogeneic bone marrow derived stem cells via infarct related artery improves long-term ventricular function in acute myocardial infarction. Cell Transplant: Oct 14, 2011 (Epub ahead of print).
3. Paul D, Samuel SM and Maulik N: Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid Redox Signal 11: 1841-1855, 2009.
4. Penn MS, Dong F, Klein S and Mayorga ME: Stem cells for myocardial regeneration. Clin Pharmacol Ther 90: 499-501, 2011.
5. Abdel-Latif A, Bolli R, Tleyjeh IM, et al: Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167: 989-997, 2007.
6. Dayan V, Yannarelli G, Billia F, et al: Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res Cardiol 106: 1299-1310, 2011.
7. Ramos GA and Hare JM: Cardiac cell-based therapy: cell types and mechanisms of actions. Cell Transplant 16: 951-961, 2007.
8. Gnecchi M, Zhang Z, Ni A and Dzau VJ: Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 103: 1204-1219, 2008.
9. Cselenyák A, Pankotai E, Horváth E, Kiss L and Lacza Z: Mesenchymal stem cells rescue cardiomyoblasts from cell death in an in vitro ischemia model via direct cell-to-cell connections. BMC Cell Biol 11: 29, 2010.
10. Plotnikov EY, Khryapenkova TG, Vasileva AK, et al: Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture. J Cell Mol Med 12: 1622-1631, 2008.
11. Wu KH, Mo XM, Han ZC and Zhou B: Stem cell engraftment and survival in the ischemic heart. Ann Thorac Surg 92: 1917-1925, 2011.
12. Singla DK, Singla RD, Lamm S and Glass C: TGF-beta2 treatment enhances cytoprotective factors released from embryonic stem cells and inhibits apoptosis in infarcted myocardium. Am J Physiol Heart Circ Physiol 300: H1442-H1450, 2011.
13. Singla DK and McDonald DE: Factors released from embryonic stem cells inhibit apoptosis of H9c2 cells. Am J Physiol Heart Circ Physiol 293: H1590-H1595, 2007.
14. Lichtenauer M, Mildner M, Hoetzenecker K, et al: Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical study. Basic Res Cardiol 106: 1283-1297, 2011.
15. Yao Y, Zhang F, Wang L, et al: Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. J Biomed Sci 16: 74, 2009.
16. Hahn JY, Cho HJ, Kang HJ, et al: Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 51: 933-943, 2008.
17. Mangi AA, Noiseux N, Kong D, et al: Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9: 1195-1201, 2003.
18. Kubo M, Li TS, Suzuki R, Ohshima M, Qin SL and Hamano K: Short-term pretreatment with low-dose hydrogen peroxide enhances the efficacy of bone marrow cells for therapeutic angiogenesis. Am J Physiol Heart Circ Physiol 292: H2582-H2588, 2007.
19. Hausenloy DJ: Signalling pathways in ischaemic postconditioning. Thromb Haemost 101: 626-634, 2009.
20. Yellon DM and Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007.
21. Hori M and Nishida K: Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 81: 457-464, 2009.
22. Pacher P and Szabo C: Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 25: 235-260, 2007.
23. Sodhi RK, Singh N and Jaggi AS: Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Vascul Pharmacol 53: 77-87, 2010.
24. Virag L and Szabo C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375-429, 2002.
25. Ullrich O, Diestel A, Eyupoglu IY and Nitsch R: Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 3: 1035-1042, 2001.
26. Jagtap P and Szabo C: Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421-440, 2005.
27. Wang Y, Kim NS, Haince JF, et al: Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal 4: ra20, 2011.
28. Koh DW, Dawson TM and Dawson VL: Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res 52: 5-14, 2005.
29. Fiorillo C, Ponziani V, Giannini L, et al: Protective effects of the PARP-1 inhibitor PJ34 in hypoxic-reoxygenated cardiomyoblasts. Cell Mol Life Sci 63: 3061-3071, 2006.
30. Oh KS, Lee S, Yi KY, Seo HW, Koo HN and Lee BH: A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4- methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia. J Pharmacol Exp Ther 328: 10-18, 2009.
31. Song ZF, Ji XP, Li XX, Wang SJ, Wang SH and Zhang Y: Inhibition of the activity of poly(ADP-ribose) polymerase reduces heart ischaemia/reperfusion injury via suppressing JNK-mediated AIF translocation. J Cell Mol Med 12: 1220-1228, 2008.
32. Liaudet L, Mabley JG, Soriano FG, et al: Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med 164: 1213-1220, 2001.
33. Pankotai E, Cselenyak A, Ratosi O, Lorincz J, Kiss L and Lacza Z: The role of mitochondria in direct cell-to-cell connection dependent rescue of postischemic cardiomyoblasts. Mitochondrion 12: 352-356, 2012.
34. Palma PF, Baggio GL, Spada C, Silva RD, Ferreira SI and Treitinger A: Evaluation of annexin V and Calcein-AM as markers of mononuclear cell apoptosis during human immunodeficiency virus infection. Braz J Infect Dis 12: 108-114, 2008.
35. Dimmeler S, Burchfield J and Zeiher AM: Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 28: 208-216, 2008.
36. Uemura R, Xu M, Ahmad N and Ashraf M: Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 98: 1414-1421, 2006.
37. Burkle A: Physiology and pathophysiology of poly(ADP-ribosyl)ation. Bioessays 23: 795-806, 2001.
38. Oliveira NG, Castro M, Rodrigues AS, et al: Effect of poly(ADP-ribosyl)ation inhibitors on the genotoxic effects of the boron neutron capture reaction. Mutat Res 583: 36-48, 2005.
39. Vinod KR, Chandra S and Sharma SK: Evaluation of 5-aminoisoquinoline (5-AIQ), a novel PARP-1 inhibitor for genotoxicity potential in vitro and in vivo. Toxicol Mech Methods 20: 90-95, 2010.
40. Kimes BW and Brandt BL: Properties of a clonal muscle cell line from rat heart. Exper Cell Res 98: 367-381, 1976.
41. Sardao VA, Oliveira PJ, Holy J, Oliveira CR and Wallace KB: Vital imaging of H9c2 myoblasts exposed to tert-butylhydroperoxide - characterization of morphological features of cell death. BMC Cell Biol 8: 11, 2007.